Globenewswire·2026-02-03 21:05Core Viewpoint - Adial Pharmaceuticals, Inc. will implement a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement and enhance its capital markets profile [1][3][4] Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 27.8 million to about 1.1 million, while maintaining the ownership percentage of each shareholder [2] - The reverse stock split will take effect on February 5, 2026, at 11:59 p.m. Eastern Time, with trading on a split-adjusted basis starting February 6, 2026 [1][2] - There will be no change to the total number of authorized shares as per the Company's Certificate of Incorporation [2] Group 2: Strategic Intentions - The reverse stock split aims to bring the Company into compliance with Nasdaq's minimum bid price requirement of at least $1.00 per share [3] - The action is expected to make the bid price more attractive to a wider range of institutional and retail investors [3][4] - The Company remains optimistic about its future and is focused on advancing its lead product, AD04, for the treatment of Alcohol Use Disorder [4][5] Group 3: Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders [5] - The lead investigational drug, AD04, is a genetically targeted serotonin-3 receptor antagonist aimed at treating Alcohol Use Disorder in heavy drinking patients [5] - The Company plans to conduct a new Phase 3 clinical trial program for AD04, which has shown promising results in reducing drinking without significant safety concerns [5]